Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 2,410 Shares of Zoetis Inc. (NYSE:ZTS)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,982 shares of the company's stock after selling 2,410 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Zoetis were worth $4,525,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Rakuten Securities Inc. lifted its stake in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the last quarter. Navigoe LLC bought a new position in Zoetis in the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in Zoetis during the fourth quarter worth approximately $44,000. Sound Income Strategies LLC boosted its holdings in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares during the period. Finally, Bfsg LLC boosted its holdings in shares of Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the period. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.18% of the company's stock.

Zoetis Stock Down 0.8%

Shares of NYSE ZTS opened at $156.01 on Friday. The stock has a market capitalization of $69.46 billion, a P/E ratio of 28.01, a PEG ratio of 2.61 and a beta of 0.94. The stock's fifty day moving average is $160.25 and its 200 day moving average is $162.87. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.28%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is presently 35.91%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, UBS Group lowered their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.